Infection parameters (ITT population). (A) Total infection score (mean, 95% CI) by 3-month interval with mavorixafor vs placebo. (B) Annualized infection rate (mean, 95% CI) by 3-month interval with mavorixafor vs placebo. (C) Annualized infection rate (mean, 95% CI) with CTCAE grade ≥3 by 3-month interval with mavorixafor vs placebo. (D) Proportion of participants experiencing infection events. CTCAE, Common Terminology Criteria for Adverse Events.